您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Acrivastine(BW825C)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Acrivastine(BW825C)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Acrivastine(BW825C)图片
CAS NO:87848-99-5
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
10mg电议
50mg电议
100mg电议

产品介绍
Acrivastine (BW825C) (BW825C) 是一种短效组胺 1 受体拮抗剂,用于治疗过敏性鼻炎。
Cas No.87848-99-5
别名阿伐斯汀; BW825C
Canonical SMILESO=C(O)/C=C/C1=NC(/C(C2=CC=C(C)C=C2)=C/CN3CCCC3)=CC=C1
分子式C22H24N2O2
分子量348.44
溶解度DMSO : 10.45 mg/mL (29.99 mM)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Acrivastine (BW825C) is a short acting histamine 1 receptor antagonist for the treatment of allergic rhinitis.

Acrivastine (usually 8mg three times daily) is an effective and well tolerated antihistamine in the treatment of chronic urticaria and allergic rhinitis. Acrivastine is more effective than placebo and similar in efficacy to clemastine or terfenadine in the treatment of seasonal allergic rhinitis. In the treatment of dermatoses in which histamine has a pathogenetic role, the efficacy of acrivastine is superior to that of placebo and similar to that of usual dosages of clemastine, hydroxyzine, chlorpheniramine, cyproheptadine or terfenadine. Acrivastine causes less drowsiness than clemastine, the incidence of adverse effects being indistinguishable from that with placebo or terfenadine[1]. Both 4 mg and 8 mg acrivastine alleviate the symptoms of seasonal allergic rhinitis with significant improvements in the symptom scores for sneezing, running nose and the calculated overall score. In addition, 8 mg acrivastine reduces the symptom scores for watery eyes and itchy throat. Acrivastine is both well tolerated and effective in the treatment of seasonal allergic rhinitis[2].

[1]. Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41(6):927-40. [2]. Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4.